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Abstract 
Keap1 is a negative regulator of Nrf2, a master transcription factor that regulates 
cytoprotection against oxidative and electrophilic stresses. Although several studies 
have suggested that the Keap1-Nrf2 system contributes to bone formation besides the 
maintenance of redox homeostasis, how Nrf2 hyperactivation by Keap1-deficiency 
affects the bone formation remains to be explored, as the Keap1-null mice are juvenile 
lethal. To overcome this problem, we utilized viable Keap1-deficient mice that we have 
generated by deleting the esophageal Nrf2 in Keap1-null mice (NEKO mice). We found 
that the NEKO mice exhibit small body size and low bone density. Although 
nephrogenic diabetes insipidus has been observed in both the NEKO mice and renal 
specific Keap1-deficient mice, the skeletal phenotypes are not recapitulated in the renal 
specific Keap1-deficient mice, suggesting that the skeletal phenotype by Nrf2 
hyperactivation is not related to the renal phenotype. Experiments with primary culture 
cells derived from Keap1-null mice showed that differentiation of both osteoclasts and 
osteoblasts were attenuated, demonstrating that impaired differentiation of osteoblasts 
rather than osteoclasts is responsible for bone hypoplasia caused by Nrf2 
hyperactivation. Thus, we propose that the appropriate control of Nrf2 activity by 
Keap1 is essential for maintaining bone homeostasis. 
(194/200 words) 
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Introduction 
Bone homeostasis is believed to be maintained on the balance between formation and 
resorption mediated by osteoblasts and osteoclasts, respectively (Manolagas, 2000). 
Reactive oxygen species (ROS) have been implicated as an important factor regulating 
the bone homeostasis. Several in vitro and in vivo studies reported that increased 
oxidative stress shows negative effects on bone formation by modulating differentiation 
and survival of osteoblasts (Mody et al, 2001; Lean et al, 2003; Bai et al, 2004; Jun et al, 
2008). Clinical studies have also demonstrated that dysregulation of the antioxidant 
system and subsequent ROS accumulation are both important mediators of bone loss 
(Asagiri and Takayanagi, 2007). However, it remains to be clarified how oxidative 
stresses induce bone loss. 
Transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) plays a key 
role in the cytoprotection from oxidative stress and xenobiotic stress (Itoh et al, 1997; 
Suzuki et al, 2013). Under unstressed conditions, Nrf2 protein level is maintained at low 
level as Nrf2 is ubiquitinated by Keap1 (Kelch-like ECH-associated protein 1)-based 
ubiquitin E3 ligase complex and degraded by the proteasome (Itoh et al, 1999; 
Kobayashi et al, 2004; Suzuki and Yamamoto, 2015). Upon the exposure to oxidative 
and/or xenobiotic stresses that inactivates Keap1, Nrf2 is stabilized and activates 
transcription of various cytoprotective genes, conferring resistance against the stresses 
(Suzuki and Yamamoto, 2017). 
It has been reported that osteoclast differentiation is enhanced by Nrf2 deficiency 
(Hyeon et al, 2013) and suppressed by Nrf2 activation through deletion of Keap1 (Sakai 
et al, 2017), suggesting that Nrf2 suppress bone resorption and subsequently promote 
bone formation. In contrast, overexpression of Nrf2 negatively regulate 
osteoblastgenesis of MC3T3-E1 cells (Hinoi et al, 2006). Although these observations 
suggest that differentiation of both osteoclasts and osteoblasts is suppressed by Nrf2 
activation, physiological effects of the Nrf2 activation on bone development have not 
been fully clarified yet. 
Nrf2 is constitutively activated in Keap1-null mouse (Wakabayashi et al, 2003), so 
that the Keap1-null mouse is a good model for the understanding of physiological 
contribution of Nrf2 activation to bone homeostasis. However, juvenile lethal due to 
hyperkeratosis in the upper digestive tract, which leads to the obstruction of the 
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esophagus and death by starvation made it infeasible to assess the effects of 
Keap1-deficiency on bone homeostasis (Wakabayashi et al, 2003). In this study, 
therefore, we decided to utilize a viable mouse model harboring systemic activation of 
Nrf2, in which a squamous epithelium-specific Nrf2-deficiency in the context of 
systemic Keap1-deficiency (Keap1–/–::Nrf2Flox/Flox::K5-Cre or NEKO mice) corrects the 
hyperkeratosis of the esophagus, and subsequent lethality, while hyperactivation of Nrf2 
is observed in most tissues, with the exception of the esophagus and skin (Suzuki et al, 
2017). We found that NEKO mice exhibited small body size and low bone density. 
Experiments with primary cells derived from Keap1-null mice indicates that 
differentiation of both osteoclasts and osteoblasts is attenuated, indicating that Nrf2 
activation inhibits differentiation of both osteoclasts and osteoblasts. These results 
support the notion that reduction of bone formation in NEKO mice is due to inhibition 
of osteoblast differentiation by Nrf2 activation and that Nrf2 activation lead to 
hypoplasia of bone mass by impairing differentiation of osteoblasts. 
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Results 
NEKO mice exhibit bone hypoplasia 
To investigate function of Nrf2 on bone development, we examined Keap1-null mice in 
which Nrf2 is constitutively activated. Because of their juvenile lethality due to 
hyperkeratosis of esophagus (Wakabayashi et al, 2003), it has been difficult to examine 
adult Keap1-null mice. We generated NEKO mice that are able to survive until 
adulthood. NEKO mice harbor hyperactivation of Nrf2 in most tissues with the 
exception of the esophagus and skin (Suzuki et al, 2017). 
We first examined whole appearance of the mouse using X-ray photography (Fig 
1A,B). The picture showed that NEKO mouse was smaller than control mouse, but 
skeletal malformation was not observed in NEKO mice (Fig 1A,B). This phenotype was 
not observed in the Keap1–/–::Nrf2–/– mice (Wakabayashi et al, 2003), indicating that the 
skeletal phenotype is due to hyperactivation of Nrf2. Consistent with the small body of 
NEKO mice, femur length of NEKO mice is significantly smaller than that of control 
mice (Fig 1C,D), indicating the impaired growth of NEKO mice. 
To further investigate bone mass, we examined femur of NEKO and control mice 
at age of 8-10 weeks by 3-dimensional reconstruction CT imaging (Fig. 2A,B). Whole 
appearance of femur from NEKO mice shows increased radiolucency and smaller bone 
size (Fig. 2A,B). Cross-section image of femur visually shows that thinner cortical bone 
and sparser trabecular bone in NEKO mice (Fig. 2C,D). Bone morphometric parameters 
were also assessed from proximal to distal area of femur with a µCT analysis program. 
Consistent with the 3-dimensional reconstruction imaging results, a dramatic decrease 
in cortical bone thickness (Ct. Th., Fig. 2E), volume bone mineral density (vBMD., Fig. 
2F) and cortical bone tissue mineral density (CB. TMD., Fig. 2G) in NEKO mice.  
The decrease of bone mass was reproducibly observed even in elder NEKO mice 
(Fig S1A-C). Showing very good agreement with the result of femur, three-dimensional 
reconstruction image of cranial bone displays that the radiolucency is increased in 
NEKO mice compared to control mice (Fig S2A-D), while no malformation in NEKO 
mice is observed (Fig S2A-D). While intensity of Alcian blue-positive cartilage in 
growth plate tends to be decreased in NEKO mice (Fig S3), thickness of femur growth 
plate was not affected in the mice, suggesting that chondrogenesis is also mildly 
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affected by Keap1 deficiency. In addition, blood ionized calcium level of NEKO mice 
was lower than that of control mice (Fig. 2H), indicating that the severe bone 
hypoplasia leads to reduction of blood ionized calcium level in NEKO mice. These 
results demonstrate that hyperactivation of Nrf2 leads to severe bone hypoplasia in 
mouse. 
 
Bone hypoplasia of NEKO mice is not linked to their renal failure 
Because NEKO mice display nephrogenic diabetes insipidus (Suzuki et al, 2017), we 
tested whether bone hypoplasia of NEKO mice is due to their renal dysfunction. To this 
end, we examined kidney-specific Keap1-deficient mice 
(Keap1Flox/Flox::Pax8-rtTA::tetO-Cre, or Keap1 TKO mice), and treated the mice with 
DOX from the embryonic stage, by administration of DOX to the pregnant mother. The 
Keap1 gene was specifically deleted in the renal tubular cells, and the Keap1 TKO mice 
displays nephrogenic diabetes insipidus, like NEKO mice (Suzuki et al, 2017). Femur 
length of Keap1 TKO mice is comparable to that of control mice (Fig. S3A,B). X-ray 
photography and 3-dimensional reconstruction imaging shows no different appearance 
between Keap1 TKO and control mice (Fig. S3C,D and S4A-D). In addition, there is no 
difference of bone morphometric parameters and blood ionized calcium level between 
Keap1 TKO and control mice (Fig. S4E-H), demonstrating that the severe bone 
hypoplasia in NEKO mice is not attributable to their renal dysfunction. 
 
Nrf2 hyperactivation leads to perturbation of bone homeostasis 
We next investigated how Keap1-deficiency affects the differentiation of osteoblasts 
and osteoclasts. First, we conducted in vitro differentiation experiments of osteoclasts 
using bone marrow (BM)-derived cells from NEKO and control mice. The BM cells 
were cultured in the medium supplemented with M-CSF and RANKL (Fig. 3A). After 
two-day pre-culture with M-CSF, RANKL was added to induce osteoclast 
differentiation. Five days after the induction, mature differentiated osteoclasts were 
visualized by TRAP staining. Whereas control BM cells produced the largest number of 
TRAP-positive multi-nucleated mature osteoclasts (Fig. 3B), NEKO mouse-derived BM 
cells produced fewer or practically no osteoclasts (Fig. 3C). This showed very good 
agreement with the previous report that osteoclast differentiation of splenic cells from 
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Keap1-deficient mice was impaired (Sakai et al, 2017). These results indicate that Nrf2 
activation suppresses osteoclast differentiation. 
Because NEKO mice showed severe bone hypoplasia despite the diminished 
osteoclast production from BM cells, we surmised that osteoblast differentiation might 
also be impaired in NEKO mice. To address this hypothesis, we conducted in vitro 
osteoblast differentiation experiment using newborn calvarias of Keap1+/– and Keap1–/– 
mice. Collected cells were pre-cultured for two days and induced to differentiate to 
osteoblasts by adding ascorbic acid, dexamethasone and β-glycerophosphate (Fig. 3D). 
Osteoblast differentiation was examined by measuring alkaline phosphatase (AP) 
staining. While the osteoblast differentiation of cells from Keap1+/– mice was nicely 
observed, that of Keap1–/– mice were severely impaired (Fig. 3E). Taken together, these 
results thus indicate that Nrf2 suppresses osteoblast differentiation and that reduction of 
bone mass in NEKO mice is due to impaired bone homeostasis by decreased osteoblast 
differentiation. 
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Discussion 
It has been shown that the Keap1-deficient mouse is a useful model for the study of 
Nrf2 hyperactivation, the juvenile lethality of mice hampers uses of the mice 
(Wakabayashi et al, 2003). To overcome this difficulty, we recently generated alive 
model of Keap1-null mouse referred to as NEKO mouse (Suzuki et al, 2017). In this 
study, we examined pathophysiological contribution of Nrf2 activation to bone 
formation utilizing the NEKO mice. We found that hyperactivation of Nrf2 leads to low 
bone density. This novel phenotype of Nrf2 activation is independent of nephrogenic 
diabetes insipidus identified in NEKO mice in the previous study (Suzuki et al, 2017). 
Primary culture experiments using newborn calvarias cells from Keap1-null mice 
indicate that impaired osteoblast differentiation is responsible for bone hypoplasia 
caused by the Nrf2 hyperactivation. These results indicate that the Nrf2 hyperactivation 
leads to bone hypoplasia. 
The finding that osteoblast differentiation of primary newborn calvarias cells is 
impaired by the Keap1-deficiency is consistent with the previous observation that Nrf2 
overexpression in osteoblastic MC3T3 cells showed osteoblast differentiation defects 
(Hinoi et al, 2006). Nrf2 has been reported to interact with Runx2, a master 
transcription factor of osteoblastgenesis, and interferes with the Runx2-dependent 
transcriptional activation (Hinoi et al, 2006). Although Nrf2 in general acts as an 
activator (Katoh et al, 2001; Sekine et al, 2016), in certain context Nrf2 acts as a 
suppressor of gene expression; for instance, genes for inflammatory cytokines 
(Kobayashi et al, 2016). Therefore, the repressor function of Nrf2 for Runx2 gene could 
be a plausible mechanism underlying the impaired osteoblastgenesis by Nrf2. Another 
report showed that some members of leucine zipper (bZIP) transcriptional factors. such 
as C/EBPβ and ATF4, are involved in osteoblastgenesis (He et al, 2001), implying that 
Nrf2 might compete with the other bZIP members for their binding sequence. Moreover, 
a recent report shows that Nrf2 activation impairs quiescence and bone marrow 
reconstitution capacity of hematopoietic stem cells (Murakami et al, 2017), implying 
that supply of osteoblasts may be impaired by the Nrf2 activation. Regarding molecular 
mechanism of Nrf2-mediated suppression of osteoclastgenesis, we recently found that 
Keap1-deficient macrophages are unable to differentiate into osteoclasts in vitro via 
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attenuation of RANKL-mediated signaling and expression of NFATc1 (nuclear factor 
of activated T cells cytoplasmic 1) (Sakai et al, 2017). 
In light of the use of Nrf2-inducing compounds as potential medical treatments, 
many studies have shown that pharmacological Nrf2 induction gives rise to a protective 
effect against a variety stresses, including ischemia-reperfusion injury (Nezu et al, 2017), 
carcinogenesis (Kensler and Wakabayashi, 2010) and inflammation (Keleku-Lukwete et 
al, 2017; Kobayashi et al, 2016). Although there are many papers that have assessed 
effects of Nrf2-induing chemicals (Kensler et al, 2013; Suzuki and Yamamoto, 2017), to 
our knowledge it has never been verified that such Nrf2 inducers provoke impairment 
of bone homeostasis. In this regard, we previous found that Nrf2 induction during 
development cause nephrogenic diabetes insipidus (Suzuki et al, 2017), but the Nrf2 
induction during adulthood will not cause such adverse effects in the kidney. These 
observations suggest that the Nrf2-inducer treatment may have a critical period during 
development. Further investigations are necessary to clarify whether Nrf2 is actually 
induced in bone cells under physiological or pathological condition. 
Of note, de novo mutations in human NRF2 gene that induce NRF2 were recently 
identified (Huppke et al, 2017), and the cases with the NRF2 induction displayed mild 
developmental delay, short stature and delayed bone age (Huppke et al, 2017). The 
phenotypes observed in the cases are consistent with the phenotype we have observed in 
the NEKO mice, including the small body length and low bone density. These 
observations in human cases and in NEKO mouse analysis in combination support the 
contention that the Nrf2 hyperactivation in certain developmental window leads to the 
impairment of bone formation and homeostasis. 
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Experimental procedures 
Mice 
Generation of esophageal Nrf2-deficient and systemic Keap1-null mice (NEKO, 
Keap1-/-::Nrf2Flox/Flox::Keratin5-Cre) and renal tubule-specific Keap1 knockout mice 
(Keap1 TKO, Keap1Flox/Flox::Pax8-rtTA::TetO-Cre) were described previously (Suzuki 
et al, 2017). For analysis of NEKO mice, littermate mice (Nrf2Flox/Flox::K5-Cre:Keap1+/– 
or Nrf2Flox/Flox::Keap1+/––) were used as controls. For analysis of Keap1 TKO mice, 
littermate mice (Keap1Flox/Flox or Keap1Flox/Flox::Pax8-rtTA) were used as controls. 
Pregnant female mice were fed with 1-mg/ml doxycyline (DOX) in the drinking water. 
Blood samples were collected from the mice and analyzed using iSTAT-1 analyzer 
(Abott) for blood ionized calcium (Ca) level. All mice were kept in 
specific-pathogen-free conditions and were treated according to the regulations of The 
Standards for Human Care and Use of Laboratory Animals of Tohoku University and 
Guidelines for Proper Conduct of Animal Experiments of the Ministry of Education, 
Culture, Sports, Science, and Technology of Japan. 
 
Osteoblast differentiation culture 
For in vitro osteoblast differentiation, newborn calvarias were digested with 1-mg/ml 
collagenase (Wako) and 2-mg/mL Dispase (Gibco) at 37°C for 15 minutes with the 
repeat of this at least 5 times. The cells were then cultured withα-MEM (Wako) with 
10% FBS for 5-7 days. After primary culture cells were treated with 0.25% 
Trypsin-EDTA solution (Sigma), cells were cultured in osteogenic medium (50-μM 
ascorbic acid, 10-nM dexamethasone, and 10-mM β-glycerophosphate) for 14 days. For 
quantifying alkaline phosphatase (ALP) activity, ALP assay was performed as 
described (Nishikawa et al, 2010). For quantitative analysis, the densities of scanned 
images of stained plate were measured using Image J software.  
 
Osteoclast differentiation culture 
The in vitro osteoclast differentiation was conducted as described (Nishikawa et al, 
2010). Briefly, bone marrow cells were flushed out from femur and tibia of female mice 
in each genotype at 7-10 weeks. The cells were cultured in 10% FBS-αMEM with 10 
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ng/ml of M-CSF (R&D Systems) for 2 days, and osteoclast precursor cells were 
obtained. The cells were cultured in 10% FBS-αMEM with 50-ng/ml RANKL (Oriental 
Yeast) in the presence of 10-ng/ml M-CSF for additional 5 days. Quantification of 
tartrate-resistant acid phosphatase (TRAP) activity was performed by TRACP & ALP 
double-stain Kit (Takara). To evaluate osteoclast differentiation, TRAP-positive 
multi-nucleated cells were counted as mature osteoclasts. For quantitative analysis, the 
densities of scanned images of stained plate were measured using Image J software. 
 
Microcomputed tomography analysis 
Whole body or full length of femur of several stage female mice was µCT scanned with 
a Latheta LCT-200 (Hitachi-Aloka) to analyze bone shape, lipid volume and bone 
morphometry. Three-dimensional reconstruction images of bone were obtained by 
Amira (M@xnet). 
 
Alcian blue staining 
Femurs were fixed in 70% ethanol, decalcified paraffin-embedded, and sectioned to 
stain with Alcian blue. For quantitative analysis, the densities and thickness of scanned 
images were measured using Image J software. 
 
Statistical analyses 
Data are expressed as the mean ± SE. For statistical analysis, pairwise comparisons 
were made by Mann-Whitney U test. P-values < 0.05 were considered statistically 
significant. 
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Figure legends 
 
Figure 1 NEKO mice show small body and femur length 
(A, B) X-ray photographs of whole mouse body of control (A) and NEKO (B) 
littermate male mice at 8-10 weeks. Scale bars, 1.5 cm. (C) The representative femur 
appearance of control (left) and NEKO (right) mice. Right femur of male mice at 8-10 
weeks. Scale bars, 5 mm. (D) Femur length from proximal end of macro-nodular or 
femur head to the distal end of femur of control (n=6) and NEKO (n=6) male mice. 
*p<0.05. 
 
Figure 2 NEKO mice show decreased bone mass compared to control mice 
(A-D) Three-dimensional re-constructional images of femurs from µCT analysis 
obtained from 8-10 week-old control and NEKO male mice. (A, B) Representative 
overview of femur. Scale bars, 2.5 mm. (C, D) The representative cross sections of 
distal femur at 0.3-0.8 mm above the distal growth plate. Scale bars, 500 µm. (E-G) 
Bone morphometric parameters assessed with a µCT analysis program of femur of 8-10 
week-old control (n=3) and NEKO (n=3) male mice. (E) Average cortical thickness (Ct. 
Th) of control (black) and NEKO (red) mice. (F) Volume bone mineral density (vBMD) 
of control (black) and NEKO (red) mice. (G) Cortical bone tissue mineral density (CB. 
TMD) of control (black) and NEKO (red) mice. Data are means ± SE. *p<0.05, 
**p<0.01. (H) Blood ionized calcium (Ca) level in control (n=5) and NEKO (n=6) 
mixed-gender mice at 3-6 weeks of age. Data are means ± SE. **p<0.01. 
 
Figure 3 Nrf2 activation suppresses both osteoclastgenesis and osteoblastgenesis 
(A) Osteoclast differentiation protocol. Osteoclast progenitor cells were obtained from 
femur of 6-8-week-old NEKO and control littermate mixed gender mice, and were 
cultured with M-CSF and RANKL. (B, C) Representative images of cultured 
osteoclasts obtained from femur of control (B) and NEKO (C) mixed gender mice were 
subjected to TRAP staining. Scale bars, 100 µm. (D) Relative intensity of TRAP 
staining of cultured osteoclasts obtained from femur of control (n=3) and NEKO (n=3) 
mice. Data are means ±  SE. *p<0.05. (E) Osteoblast differentiation protocol. 
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Newborn calvarias were digested with collagenase and Dispase, and harvested in 
α-MEM medium. After several passages, the osteoblast cells were cultured with 
osteoblast differentiation medium. Keap1+/– and Keap1–/– osteoblast cells were cultured 
with ascorbic acid, ß-glycerophosphate and dexamethasone for 14 days. (F) Cultured 
cells were stained with ALP staining at each time point. Representative data are shown. 
(G) Relative intensity of ALP staining of cultured osteoblasts obtained from Keap1+/– 
(n=3) and Keap1–/– (n=3) mice. Data are means ± SE. *p<0.05. 
